Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT03237390
Last Updated: 2023-01-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
43 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-01-04
Study Completion Date
2022-05-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and best dose of ribociclib and gemcitabine hydrochloride in treating patients with solid tumors that have spread to other places in the body. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and gemcitabine hydrochloride may work better in treating patients with solid tumors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
NCT03009201
Advanced Soft Tissue Sarcoma
Locally Advanced Angiosarcoma
Locally Advanced Leiomyosarcoma
+24 more
COMPLETED
PHASE1
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
NCT01237236
Advanced Solid Tumor
Lymphomas
COMPLETED
PHASE1
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00607724
Unspecified Adult Solid Tumor, Protocol Specific
COMPLETED
PHASE1
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
NCT04601402
Solid Tumor
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
+1 more
COMPLETED
PHASE1
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
NCT00098501
Unspecified Adult Solid Tumor, Protocol Specific
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To describe the dose-limiting toxicities and identify the maximum tolerated dose (MTD) and recommended phase II dose of the combination of ribociclib and gemcitabine hydrochloride (gemcitabine) in patients with advanced solid tumors.
SECONDARY OBJECTIVES:
I. To describe the safety and tolerability of the combination of ribociclib and gemcitabine.
II. To describe the pharmacokinetic (PK) of ribociclib in combination with gemcitabine.
III. To describe preliminary evidence of efficacy of the combination of ribociclib and gemcitabine.
TERTIARY OBJECTIVES:
I. To evaluate the correlation of CDK4/6, cyclin D1 and cyclin D3 amplification, retinoblastoma (RB) and P16 expression in archived and biopsied tumor tissue with treatment response.
OUTLINE: This is a dose-escalation study.
Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8 and ribociclib orally (PO) once daily (QD) on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
I. To describe the dose-limiting toxicities and identify the maximum tolerated dose (MTD) and recommended phase II dose of the combination of ribociclib and gemcitabine hydrochloride (gemcitabine) in patients with advanced solid tumors.
SECONDARY OBJECTIVES:
I. To describe the safety and tolerability of the combination of ribociclib and gemcitabine.
II. To describe the pharmacokinetic (PK) of ribociclib in combination with gemcitabine.
III. To describe preliminary evidence of efficacy of the combination of ribociclib and gemcitabine.
TERTIARY OBJECTIVES:
I. To evaluate the correlation of CDK4/6, cyclin D1 and cyclin D3 amplification, retinoblastoma (RB) and P16 expression in archived and biopsied tumor tissue with treatment response.
OUTLINE: This is a dose-escalation study.
Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8 and ribociclib orally (PO) once daily (QD) on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (gemcitabine hydrochloride, ribociclib)
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Gemcitabine Hydrochloride
Intervention Type
DRUG
Given IV
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Pharmacological Study
Intervention Type
OTHER
Correlative studies
Ribociclib
Intervention Type
DRUG
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemcitabine Hydrochloride
Given IV
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Pharmacological Study
Correlative studies
Intervention Type
OTHER
Ribociclib
Given PO
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
dFdCyd
Difluorodeoxycytidine Hydrochloride
Gemzar
LY-188011
LY188011
Kisqali
LEE-011
LEE011
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of advanced/metastatic solid malignancy for which no standard treatment option exists that will confer clinical benefit
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Dose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
* Ability to provide written informed consent which must be obtained prior to any screening procedures and according to local guidelines
* Life expectancy of \>= 12 weeks
* Absolute neutrophil count \>= 1500/mm\^3
* Platelets \>= 100,000/mm\^3
* Hemoglobin \>= 9 g/dL
* Potassium \>= lower limit of normal (LLN) range for the institution
* Calcium \>= LLN (corrected for serum albumin, if albumin abnormal)
* Magnesium \>= LLN
* Sodium \>= LLN
* Phosphorus \>= LLN; NOTE: Supplementation may be given before the first dose of study medication
* International normalized ratio (INR) =\< 1.5
* Serum creatinine =\< 1.5 mg/dL or creatinine clearance \>= 50 mL/min (calculated by Cockcroft Gault equation)
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x upper limit of normal (ULN) or =\< 5 x ULN if liver metastases are present
* Total bilirubin =\< 3.0 x ULN; if patient has known Gilbert?s syndrome direct bilirubin =\< 1.5 x ULN
* Standard 12-lead electrocardiography (ECG) with the following parameters at screening (defined as the mean of the triplicate ECGs):
* Fridericia's correction formula (QTcF) interval at screening \< 450 msec (using Fridericia? s correction)
* Resting heart rate 50 to 100 beats per minute
* Negative pregnancy test performed =\< 7 days prior to registration (women of childbearing potential only)
* Able to swallow ribociclib capsules
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to provide mandatory blood samples for research purposes
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Dose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
* Ability to provide written informed consent which must be obtained prior to any screening procedures and according to local guidelines
* Life expectancy of \>= 12 weeks
* Absolute neutrophil count \>= 1500/mm\^3
* Platelets \>= 100,000/mm\^3
* Hemoglobin \>= 9 g/dL
* Potassium \>= lower limit of normal (LLN) range for the institution
* Calcium \>= LLN (corrected for serum albumin, if albumin abnormal)
* Magnesium \>= LLN
* Sodium \>= LLN
* Phosphorus \>= LLN; NOTE: Supplementation may be given before the first dose of study medication
* International normalized ratio (INR) =\< 1.5
* Serum creatinine =\< 1.5 mg/dL or creatinine clearance \>= 50 mL/min (calculated by Cockcroft Gault equation)
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x upper limit of normal (ULN) or =\< 5 x ULN if liver metastases are present
* Total bilirubin =\< 3.0 x ULN; if patient has known Gilbert?s syndrome direct bilirubin =\< 1.5 x ULN
* Standard 12-lead electrocardiography (ECG) with the following parameters at screening (defined as the mean of the triplicate ECGs):
* Fridericia's correction formula (QTcF) interval at screening \< 450 msec (using Fridericia? s correction)
* Resting heart rate 50 to 100 beats per minute
* Negative pregnancy test performed =\< 7 days prior to registration (women of childbearing potential only)
* Able to swallow ribociclib capsules
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to provide mandatory blood samples for research purposes
Exclusion Criteria
* Previous anti-cancer chemotherapy, immunotherapy or investigational agents =\< 28 days prior to registration
* Received radiotherapy =\< 28 days or limited field radiation for palliation =\< 14 days prior to registration, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom \>= 25% of the bone marrow was irradiated
* Major surgery =\< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
* Active clinically serious infections or other serious uncontrolled medical conditions
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
* Baseline neuropathy of \> grade 2
* Known hypersensitivity to any of the excipients of ribociclib
* Known human immunodeficiency virus (HIV) patients with active and untreated disease
* Central nervous system (CNS) involvement unless they meet ALL of the following criteria:
* \>= 28 days from prior therapy completion (including radiation and/or surgery) to registration
* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
* Clinically significant, uncontrolled heart disease and/ or cardiac repolarization abnormalities including any of the following:
* History of unstable angina pectoris, symptomatic pericarditis, myocardial infarction, coronary artery bypass grafting or coronary angioplasty =\< 12 months prior to registration
* History of documented congestive heart failure (New York Heart Association functional classification III - IV)
* Documented cardiomyopathy
* Left ventricular ejection fraction (LVEF) \< 50% as determined by echocardiogram (ECHO)
* Clinically significant cardiac arrhythmias ( e.g ventricular tachycardia) , left bundle branch block, high-grade atrioventricular (AV) block ( e.g bifascucular block, Mobitz type II and third degree AV block)
* Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
* Risk factors for torsades de pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
* Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause torsades de pointe that cannot be discontinued (within 5 half-lives or =\< 7 days prior to registration) or replaced by safe alternative medication
* Inability to determine the QT interval on screening (QTcF, using Fridericia? s correction)
* Systolic blood pressure \> 160 mmHg or \< 90 mmHg
* Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator?s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections etc.)
* Currently receiving any of the following medications and cannot be discontinued 7 days prior to starting the study
* Herbal supplements including grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each; orange juice is allowed
* Known strong inducers or inhibitors of CYP3A4/5 including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges
* Medications known to have a narrow therapeutic window and are predominantly metabolized through CYP3A4
* Currently receiving or has received systemic corticosteroids (=\< 14 days prior to registration, or who have not fully recovered from side effects of such treatment); NOTE: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
* History of non-compliance to medical regimen or inability to grant consent
* Currently receiving warfarin or other warfarin-derived anticoagulant for treatment, prophylaxis or otherwise; Note: Therapy with heparin, direct oral anticoagulants, low molecular weight heparin (LMWH) or fondaparinux is allowed
* Participation in a prior investigational study =\< 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
* Failure to recover from all adverse events/toxicities related to prior anticancer therapies to grade 1 per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; NOTE: Exception: patients with any grade of alopecia are allowed to enter the study
* Child-Pugh score B or C (for cirrhosis patients only)
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation; highly effective contraception methods include:
* Total abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
* Male sterilization (at least 6 months prior to screening), the vasectomized male partner should be the sole partner for that patient
* Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception
* Note: In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment; Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction
* Note: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) is she considered not of child bearing potential
* Sexually active males unless they use a condom during intercourse while taking the drug and for 21 days after stopping treatment and should not father a child in this period; Note: A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
* Known standard therapy for the patient?s disease that is potentially curative or definitely capable of extending life expectancy
* Received radiotherapy =\< 28 days or limited field radiation for palliation =\< 14 days prior to registration, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom \>= 25% of the bone marrow was irradiated
* Major surgery =\< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
* Active clinically serious infections or other serious uncontrolled medical conditions
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
* Baseline neuropathy of \> grade 2
* Known hypersensitivity to any of the excipients of ribociclib
* Known human immunodeficiency virus (HIV) patients with active and untreated disease
* Central nervous system (CNS) involvement unless they meet ALL of the following criteria:
* \>= 28 days from prior therapy completion (including radiation and/or surgery) to registration
* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
* Clinically significant, uncontrolled heart disease and/ or cardiac repolarization abnormalities including any of the following:
* History of unstable angina pectoris, symptomatic pericarditis, myocardial infarction, coronary artery bypass grafting or coronary angioplasty =\< 12 months prior to registration
* History of documented congestive heart failure (New York Heart Association functional classification III - IV)
* Documented cardiomyopathy
* Left ventricular ejection fraction (LVEF) \< 50% as determined by echocardiogram (ECHO)
* Clinically significant cardiac arrhythmias ( e.g ventricular tachycardia) , left bundle branch block, high-grade atrioventricular (AV) block ( e.g bifascucular block, Mobitz type II and third degree AV block)
* Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
* Risk factors for torsades de pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
* Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause torsades de pointe that cannot be discontinued (within 5 half-lives or =\< 7 days prior to registration) or replaced by safe alternative medication
* Inability to determine the QT interval on screening (QTcF, using Fridericia? s correction)
* Systolic blood pressure \> 160 mmHg or \< 90 mmHg
* Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator?s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections etc.)
* Currently receiving any of the following medications and cannot be discontinued 7 days prior to starting the study
* Herbal supplements including grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each; orange juice is allowed
* Known strong inducers or inhibitors of CYP3A4/5 including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges
* Medications known to have a narrow therapeutic window and are predominantly metabolized through CYP3A4
* Currently receiving or has received systemic corticosteroids (=\< 14 days prior to registration, or who have not fully recovered from side effects of such treatment); NOTE: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
* History of non-compliance to medical regimen or inability to grant consent
* Currently receiving warfarin or other warfarin-derived anticoagulant for treatment, prophylaxis or otherwise; Note: Therapy with heparin, direct oral anticoagulants, low molecular weight heparin (LMWH) or fondaparinux is allowed
* Participation in a prior investigational study =\< 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
* Failure to recover from all adverse events/toxicities related to prior anticancer therapies to grade 1 per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; NOTE: Exception: patients with any grade of alopecia are allowed to enter the study
* Child-Pugh score B or C (for cirrhosis patients only)
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation; highly effective contraception methods include:
* Total abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
* Male sterilization (at least 6 months prior to screening), the vasectomized male partner should be the sole partner for that patient
* Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception
* Note: In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment; Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction
* Note: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) is she considered not of child bearing potential
* Sexually active males unless they use a condom during intercourse while taking the drug and for 21 days after stopping treatment and should not father a child in this period; Note: A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
* Known standard therapy for the patient?s disease that is potentially curative or definitely capable of extending life expectancy
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Mayo Clinic
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex Adjei
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital
Phoenix, Arizona, United States
Site Status
Mayo Clinic in Florida
Jacksonville, Florida, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma WW, Lou Y, Dy GK, Mahipal A, Weroha SJ, Wahner Hendrickson AE, Reid JM, Adjei AA. A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors. BJC Rep. 2025 Jan 14;3(1):1. doi: 10.1038/s44276-024-00107-0.
Reference Type
DERIVED
Seetharam M, Norman A, Allred J, Kong J, Opyrchal M, Ma WW, Lou Y, Dy GK, Mahipal A, Weroha J, Wahner-Hendrickson A, Reid JM, Adjei AA. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors. Res Sq [Preprint]. 2024 Apr 25:rs.3.rs-4261257. doi: 10.21203/rs.3.rs-4261257/v1.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mayo.edu/research/clinical-trials
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2017-01316
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC1613
Identifier Type: OTHER
Identifier Source: secondary_id
MC1613
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
NCT01356173
COMPLETED
PHASE1
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
NCT01540253
COMPLETED
PHASE1
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
NCT01295632
COMPLETED
PHASE1
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00016172
COMPLETED
PHASE1
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
NCT06771921
TERMINATED
PHASE1/PHASE2
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029
RECRUITING
PHASE1
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003430
COMPLETED
PHASE1
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
NCT00503451
COMPLETED
PHASE1
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01106599
COMPLETED
PHASE1
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
NCT00694083
COMPLETED
PHASE1
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
NCT02187783
COMPLETED
PHASE2
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT02915172
WITHDRAWN
PHASE1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132
RECRUITING
PHASE1/PHASE2
LY293111 in Treating Patients With Advanced Solid Tumors
NCT00006375
COMPLETED
PHASE1
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
NCT00085553
COMPLETED
PHASE1
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
TERMINATED
PHASE1
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
NCT00004057
COMPLETED
PHASE1
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
NCT02518958
COMPLETED
PHASE1
Decitabine in Treating Patients With Advanced Solid Tumors
NCT00030615
COMPLETED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004
RECRUITING
PHASE1
LBH589 and Gemcitabine in the Treatment of Solid Tumors
NCT00550199
TERMINATED
PHASE1
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
NCT00876122
COMPLETED
PHASE1
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
NCT01567163
COMPLETED
PHASE2
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
TERMINATED
PHASE1
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
NCT01604863
SUSPENDED
PHASE1